Walleye Capital LLC Trims Stake in RxSight, Inc. (NASDAQ:RXST)

Walleye Capital LLC cut its position in RxSight, Inc. (NASDAQ:RXST - Free Report) by 75.8% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 31,342 shares of the company's stock after selling 98,345 shares during the quarter. Walleye Capital LLC owned about 0.08% of RxSight worth $1,078,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Private Trust Co. NA acquired a new stake in RxSight in the fourth quarter valued at $34,000. Arcadia Investment Management Corp MI acquired a new stake in shares of RxSight in the fourth quarter valued at about $46,000. Harbor Investment Advisory LLC bought a new position in shares of RxSight during the fourth quarter worth about $52,000. Global Retirement Partners LLC bought a new stake in RxSight in the fourth quarter valued at approximately $69,000. Finally, KBC Group NV lifted its position in shares of RxSight by 71.0% in the 4th quarter. KBC Group NV now owns 2,107 shares of the company's stock worth $72,000 after purchasing an additional 875 shares during the period. 78.78% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at RxSight

In related news, Director Tamara Fountain sold 7,000 shares of RxSight stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $25.71, for a total value of $179,970.00. Following the sale, the director now owns 24,793 shares in the company, valued at $637,428.03. The trade was a 22.02 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Company insiders own 9.36% of the company's stock.

RxSight Trading Down 0.0 %

Shares of RXST traded down $0.01 during trading hours on Friday, reaching $14.73. 140,435 shares of the company's stock traded hands, compared to its average volume of 624,255. RxSight, Inc. has a 12 month low of $13.50 and a 12 month high of $66.54. The stock has a market cap of $596.23 million, a PE ratio of -17.72 and a beta of 1.26. The firm's 50 day simple moving average is $22.46 and its 200-day simple moving average is $34.20.

RxSight (NASDAQ:RXST - Get Free Report) last released its earnings results on Tuesday, February 25th. The company reported ($0.15) earnings per share for the quarter, missing analysts' consensus estimates of $0.10 by ($0.25). The firm had revenue of $40.21 million during the quarter, compared to the consensus estimate of $40.23 million. RxSight had a negative return on equity of 14.00% and a negative net margin of 23.92%. As a group, analysts expect that RxSight, Inc. will post -0.7 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have recently commented on RXST. UBS Group downgraded shares of RxSight from a "buy" rating to a "neutral" rating and reduced their price objective for the stock from $45.00 to $16.00 in a research report on Wednesday, April 9th. Wells Fargo & Company dropped their price target on shares of RxSight from $35.00 to $22.00 and set an "equal weight" rating on the stock in a research report on Thursday, April 3rd. Piper Sandler started coverage on RxSight in a report on Tuesday, April 15th. They set a "neutral" rating and a $18.00 price target for the company. Needham & Company LLC restated a "buy" rating and set a $43.00 price objective on shares of RxSight in a research note on Thursday, April 3rd. Finally, Stifel Nicolaus lowered their target price on shares of RxSight from $33.00 to $28.00 and set a "hold" rating for the company in a report on Wednesday, March 19th. Two research analysts have rated the stock with a sell rating, four have assigned a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, RxSight has an average rating of "Hold" and an average price target of $37.60.

RxSight Profile

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.